证券代码：300289 证券简称：利德曼 公告编号：2025-034 北京利德曼生化股份有限公司 第六届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司(以下简称"公司")第六届董事会第 五次会议(以下简称"本次会议")于 2025 年 8 月 26 日在北京市北京经 济技术开发区兴海路 5 号公司二层会议室以通讯方式召开。本次会议 通知于 2025 年 8 月 15 日以电子邮件方式送达全体董事，与会的各位 董事已知悉与所审议事项相关的必要信息。本次会议由董事长尧子女 士主持，应出席本次会议的董事 7 名，亲自出席会议的董事 7 名。公 司全体监事和高级管理人员列席了本次会议。本次会议的召集和召开 符合《公司法》和《公司章程》的有关规定，会议所形成的有关决议 合法、有效。经全体董事认真审议，投票表决通过以下议案： 一、审议通过《关于 2025 年半年度报告全文及摘要的议案》 董事会认为公司已严格按照相关法律、法规及中国证监会和深圳 证券交易所的规定，编制公司《2025 年半年度报告》及《2025 年半 年度 ...

Core Points - The company held its sixth supervisory board's fifth meeting on August 26, 2025, to review and approve the 2025 semi-annual report and its summary [1][2] - The supervisory board confirmed that the report complies with relevant laws, regulations, and the company's internal rules, ensuring the information is true, accurate, and complete [1] - The voting results showed unanimous approval with 3 votes in favor, 0 against, and 0 abstentions for the proposal [2] Summary by Sections - **Meeting Details** - The meeting was conducted via telecommunication and attended by three supervisors, with the chairman presiding [1] - The meeting adhered to the requirements of the Company Law of the People's Republic of China and the company's articles of association [1] - **Report Review** - The supervisory board reviewed the 2025 semi-annual report and its summary, concluding that the content accurately reflects the company's operational and financial status [1] - The report was found to meet the requirements set by the Shenzhen Stock Exchange and the China Securities Regulatory Commission [1] - **Voting Outcome** - The proposal regarding the semi-annual report was passed with a unanimous vote of 3 in favor [2]

Group 1 - The company announced that its sixth supervisory board's fifth meeting approved the proposal for the full text and summary of the 2025 semi-annual report [2]

Core Viewpoint - Lideman announced the approval of the full text and summary of the 2025 semi-annual report by its sixth board of directors at the fifth meeting [2] Group 1 - The announcement was made on the evening of August 26 [2] - The decision was made during a board meeting [2] - The report pertains to the company's performance for the first half of 2025 [2]

智通财经APP讯，利德曼(300289.SZ)发布2025年半年度报告，该公司营业收入为1.6亿元，同比减少 14.80%。归属于上市公司股东的净亏损为424.52万元。归属于上市公司股东的扣除非经常性损益的净亏 损为1055.26万元，同比扩大191.60%。基本每股亏损为0.0078元。 ...

Group 1 - Lidman (SZ 300289, closing price: 8.89 yuan) announced on August 26 that its sixth fifth board meeting was held via communication method, discussing the proposal for the full text and summary of the 2025 semi-annual report [1] - For the year 2024, Lidman's revenue composition is as follows: 90.84% from the biopharmaceutical industry, 8.98% from property leasing, and 0.17% from services [1] - As of the report date, Lidman's market capitalization is 4.8 billion yuan [1] Group 2 - The pet industry is experiencing a significant boom, with a market size of 300 billion yuan, leading to a surge in stock prices of related listed companies [1]

经济观察网 2025年8月26日，利德曼(300289)发布2025年半年度报告，2025年上半年实现营业收入1.6亿 元，同比下降14.80%；实现净利润-424.52万元，同比下降800.43%；基本每股收益-0.0078元；加权平均 净资产收益率ROE为-0.26%。 ...

智通财经APP讯，利德曼(300289.SZ)发布2025年半年度报告，该公司营业收入为1.6亿元，同比减少 14.80%。归属于上市公司股东的净亏损为424.52万元。归属于上市公司股东的扣除非经常性损益的净亏 损为1055.26万元，同比扩大191.60%。基本每股亏损为0.0078元。 ...

证券代码：300289 证券简称：利德曼 公告编号：2025-038 北京利德曼生化股份有限公司 2025年半年度报告披露提示性公告 北京利德曼生化股份有限公司 董 事 会 2025 年 8 月 26 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日召开第六届董事会第五次会议、第六届监事会第五次会议，审 议通过了《关于 2025 年半年度报告全文及摘要的议案》。 为使投资者全面了解本公司的经营成果、财务状况及未来发展规 划，公司《2025 年半年度报告》及《2025 年半年度报告摘要》于 2025 年 8 月 27 日在中国证监会指定的创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）上披露，敬请投资者注意查阅！ 特此公告。 ...

编制单位：北京利德曼生化股份有限公司 单位：人民币 元 北京利德曼生化股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 法定代表人：尧子 主管会计工作的负责人：欧阳旭 会计机构负责人：欧阳旭 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市 | 上市公司核 | 2025 年期初 | 年上半年度占用 2025 2025年上半年度 | 2025年上半年度 | 2025 年 6 月末 | 占用形成原因 | 占用性 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 算的会计科 | | 累计发生金额（不含 占用资金的利息 | 偿还累计发生金 | | | | | | | 公司的关联关系 | 目 | 占用资金余额 | 利息） （如有） | 额 | 占用资金余额 | | 质 | | 控股股东、实际控制人及其附属企 | — | — | — | | | | | | — | | 业 | | | | | | | | | | | 小计 | — | — | — | | | | | | — | | 前控股股东 ...